of either the preferred mode of administration or the efficacy of glucagon in different clinical situations and its current status in the treatment of cardiovascular disease. 5 6 In a previous paper7 we reported our initial experience with the use of continuous infusions of glucagon in the treatment of severe heart failure. The present paper describes our further experience in a variety of clinical situations in 50 patients, 40 of whom had either intractable heart failure or cardiogenic shock.
GLUCAGON IN HEART FAILURE Group 1: Patients with chronic congestive heart failure unresponsive to all other therapy, which included digitalization and an oral dosage of furosemide of at least 200 mg/day together with 100 mg/day of spironolactone (12 patients, including four in cardiogenic shock). The diagnoses were congestive cardiomyopathy (five), ischemic heart disease (five), and chronic rheumatic heart disease (two).
Group 2: Patients with acute myocardial infarction complicated by either cardiogenic shock (15 patients-group 2A) or by severe congestive heart failure with major arrhythmias (two patients-group 2B). All 15 patients with cardiogenic shock had failed to respond to an isoproterenol infusion.
Group 3: Patients with postoperative myocardial depression occurring after open-heart surgery for valve replacement (11 patients) . In nine, the aortic valve was replaced, and in one the mitral valve. One additional patient had aortic valve replacement plus mitral valvotomy. Group 4: Miscellaneous group of 10 patients. There were six patients with cardiomegaly and controlled heart failure, two with complete heart block, one with severe ischemic heart disease and congestive heart failure aggravated by propranolol (Inderal) who later developed digitalis intoxication, and one with ischemic heart disease and digitalis intoxication.
The criteria used to define cardiogenic shock were persistent hypotension with a blood pressure usually below 85 mm Hg systolic accompanied by cyanosis, sweating, cold extremities, mental clouding, and oliguria.8 9 Established criteria were used for the diagnosis of acute myocardial infarction.9' 10 Postoperative myocardial depression was considered present if cardiogenic shock or acute heart failure unresponsive to conventional therapy developed within 48 hours of operation.
The methods used were the same as described in our earlier report.7 Glucagon (Eli Lilly and Co.) freshly dissolved in a 5% dextrose solution, was given as a continuous intravenous infusion at an initial rate of 5 mg/hour. The diluent provided was not used, to avoid the possibility of administering excessive amounts of phenol."
To prevent nausea, an intramuscular injection of 12.5 mg of prochlorperazine (Stemetil) was given before starting glucagon, and in most patients in whom nausea developed later it was possible to control this with further prochlorperazine and continue the infusion; several injections were usually necessary throughout the infusion period. Prochlorperazine was not required in postoperative patients (group 3). Infusions were continued for 1-7 days depending on the response.
In the absence of a clinical response, the dosage Circulation, Volume XLV, March 1972 was increased to 10 mg/hour, and in one patient to 15 mg/hour. In six patients, the dosage had to be reduced from 5 mg/hour because of persistent nausea and vomiting. In all, 60 infusions were given to the 50 patients.
Serum electrolytes, blood urea, and liver function tests were estimated before and after, and sometimes during, the glucagon infusions. The blood sugar was estimated randomly and also in the presence of symptoms suggestive of hypoglycemia. Blood pressure, pulse rate, respiratory rate, body weight, and fluid balance were recorded throughout, and all patients with intractable heart failure (group 1) were given heparin (5000 units every 4 hours) during infusions. The 40 patients in groups 1, 2, and 3 were all nursed in an intensive care unit and had continuous electrocardiographic monitoring. Where possible, chest X-rays were obtained before and after glucagon.
Patients were classified as either responding or showing no improvement to treatment with glucagon. Minor or transient improvement not significant in the management of the case was not recorded as improvement. Patients in group 1 (intractable cardiac failure) were recorded as responding if glucagon treatment resulted in a large diuresis accompanied by rapid resolution in the signs of heart failure with correction of the abnormal serum electrolytes, blood urea, and liver function tests. Group 2 patients (acute myocardial infarction) with cardiogenic shock were recorded as responding if there was a sustained increase in blood pressure of at least 15 mm Hg, which was accompanied by a reversal of the signs of shock. Glucagon was commenced and isoproterenol was continued for varying periods depending upon the response. Those patients with severe heart failure with major arrhythmias were recorded as responding if there was reversal of the heart failure and a reduced incidence of major arrhythmias. Group 3 patients (postoperative myocardial depression) were assessed as responding if there was a reversal of the signs of shock as outlined for group 2 patients, or if there was a reversal of acute heart failure resistant to conventional therapy. Group 4 patients with controlled heart failure were recorded as responding if, after glucagon, the transverse diameter of the heart was reduced substantially (more than 2.0 cm measured from standardized chest Xrays).
Results
The results are summarized in table 1.
Group 1 Figure 1 shows the urine volumes and weight loss which occurred during an infusion in a 38-year-old man with long-standing ischemic heart disease. He had remained cyanosed and icteric with generalized edema, ascites, and the auscultatory signs of mitral and tricuspid incompetence despite intensive treatment for heart failure. A diuresis began 2 hours after glucagon was added to his therapy and continued after the inifusion was stopped.
He died at home 4 months later of pulmonary edema. Eight patients of the 12 in group 1 responded, although three of these died in the hospital and a further one died at home 4 months after discharge. Three of the eight had cardiogenic shock in addition to intractable heart failure and two of these were hospital deaths; the other, who has ischemic heart disease, remains alive 19 months after the first of three separate episodes of resistant heart failure complicated by the development of left bundle-branch block and cardiogenic shock. Each episode responded to a glucagon infusion with first an increase in blood pressure and reversal of the signs of shock, and then a change from left bundle-branch block to niormal intraventricular conduction. Another patient with ischemic heart disease also had left bundle-branch block of recent onset which reverted to normal intraventricular conduction during an infusion. He died of resistant venitricular fibrillation 2 days after completing the second of two successful glucagon inifusionls over a 3-month period. The four patients in group 1 who did not respond to glucagon all died in the hospital (see table 1 ). Group 2 Figure 2 shows the changes in heart rate anid blood pressure which occurred with the oniset of chest pain in a 56-year-old woman w,ith known ischemic heart disease and angina pectoris who had been digitalized previously. This episode occurred in the hospital. When seen a few minutes after the onset of pain, she had a loud panisystolic murmur, grade III/VI, audible at the apex and a third heart sound, neither of which had been present an hour before. An isoproterenol infusion did not increase the blood pressure or influence the initenisity of the apical systolic murmur. Within anl hour of adding glucagon, the systolic blood pressure increased from 70 to 100 mm Hg and the apical systolic murmur became softer. The glucagon dosage was then reduced from 5 to 2.5 mg/hour because of nausea, but a satisfactory blood pressure was mainitained anid the isoproterenol could be reduced and finially stopped. The apical systolic murmur became inaudible 6 hours after starting glucagon, which was stopped 24 hours later.
Her further recovery was uncomplicated. The murmur was thought to be due to acute mitral There were 10 patients in group 4 (miscellaneous) with less advanced heart disease and only two of these responded. The first was a 64-year-old woman with a history of ischemic heart disease and congestive heart failure who was taking digoxin and furosemide, in addition to propranolol (Inderal) 240 mg/day because of incapacitating angina. On admission, she had bradyeardia and was in severe heart failure with generalized edema. The electrocardiogram showed atrial fibrillation at a ventricular rate of 35 beats/mnm and widespread S-T-segment depression and Twave inversion. An isoproterenol infusion was begun but produced multiple ventricular ectopic beats and was suspended. A bolus inijection of glucagon, 1 mg intravenously, was then given and within 3 min the ventricular rate increased from 35 to 60 beats/min and the rhythm changed to sinus rhythm with frequent nodal ectopic beats. A glucagon inifusion (5 mg/hour) was then commenced; an hour later there was sinus rhythm at a rate of 100 beats/min and no ectopic beats. This wvas maintained, and a substantial diuresis with clinical improvement ensued. No further propranolol was given. We concluded that propranolol had aggravated the heart failure anid that glucagon had reversed this effect.
Two weeks later and while still hospitalized, she again developed bradycardia and became 4 were having potassium supplements, and the patients in group 1 in whom the largest diureses occurred were receiving spironolactone. Hypoglycemia developed in two patients, and this was easily controlled. One was a postoperative patient who also had cirrhosis of the liver. In the remaining patients, blood sugar levels were usually maintained at about 120 mg%. The fact that hypoglycemia did occur in these two patients and that hyperglycemia was not a problem presumably reflects the direct insulin-releasing effect of glueagon. The data obtained during continuous electrocardiographic monitoring in the 17 patients with complicated myocardial infarction show that glucagon, when used according to the regime described, does not increase the tendency to ventricular ectopic beats or major arrhythmias. Before glucagon, ventricular ectopic beats were occurring in all patients, and in no case did they increase during the infusion. In the two patients with recurrent ventricular tachycardia and ventricular fibrillation, the frequency of these arrhythmias was not increased during the glucagon; in fact, the reverse occurred. These findings support the conclusion that glucagon does not increase the "electrical instability" of the heart after acute myocardial infarction in man.7 10, 17. 18 The effects found on pacemaker tissue and the conducting system of the heart associated with the administration of glucagon in this series raise several points of interest. It is known from experimental work in dogs and cats that the inotropic and chronotropic effects of glucagon are not blocked by pretreatment with beta-adrenergic blocking drugs.2' ' The application of these findings to clinical situations was demonstrated by the results obtained in the two patients of this series in whom these drugs had produced a profound bradyeardia and a worsening of heart failure. Both responded to glucagon with an increase in heart rate and marked clinical improvement. In one patient this could be contrasted with the effect of glucagon on a bradyarrhythmia due to digitalis intoxication. As glucagon facilitates atrioventricular conduction in the dog3 19 it might have been expected to increase heart rate. However, it did not, nor did it in the one other patient treated who had atrioventricular block due to digitalis.
These latter findings are not in accord with the experimental results of Cohn, Agmon, and Gamble.20 They found that glucagon abolished over 70% of arrhythmias due to digitalis intoxication in dogs and that the production of sinus tachycardia with a 1:1 ventricular response appeared to be the principal mechanism involved. Since it is general experience that the chronotropic effect of glucagon is much less in man than in the dog,' 10, 17. 18, 21 a conclusion which the findings of the present study would support, glucagon might be expected on theoretical grounds to be less effective in the control of digitalis-induced bradyarrhythmias in man. Such was our experience in the two patients we studied.
In three patients of the series with recently developed left bundle-branch block, this reverted to normal intraventricular conduction during glucagon infusions. In one patient, this occurred on three separate occasions. The contributions of myocardial electrolyte disturbances, digoxin levels, regional ischemia, and cardiac dilatation in causing the left bundlebranch block cannot be evaluated in these patients so that it is impossible to define the role of glucagon, if any, in restoring conduction. However, these observations prompted us to use glucagon in the two patients with recently developed complete heart block unrelated to acute myocardial infarction. In neither did glucagon reverse the block. Nevertheless the findings as a whole suggest that the effects of glucagon on conduction disturbances in the heart should be further evaluated, particularly after acute myocardial infarction where the presence of conduction defects carries a high mortality22-24 and the mechanisms involved are often reversible.
Recent experiments with isolated papillary muscles have shown that while glucagon has a positive inotropic action and increases cyclic AMP in nonfailing heart muscle, it does not produce these effects in preparations obtained from failing hearts, either in the cat or in man.6 25 The results of the present study show that glucagon has a definite place in the management of patients in intractable heart failure and in postoperative myocardial depression when used as an adjunct to conventional therapy. It is effective clinically in reversing bradycardia and myocardial depression due to beta-adrenergic blocking drugs. There is no evidence from this series that it initiates or aggravates a tendency to arrhythmias after myocardial infarction when used as a constant infusion. Glucagon is useful in the treatment of severe heart failure after myocardial infarction when major arrhythmias are occurring and may occasionally be effective in the treatment of cardiogenic shock. It has no place at present in the routine management of patients with congestive heart failure, in our view, because of the nausea an effective dose commonly produces and the necessity for parenteral administration. 
